Botulinum toxins for the prevention of migraine in adults

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 4, 2015, Pages

  Herd, Clare P ^a   Sinclair, Alexandra ^a   Ives, Natalie ^a   Rick, Caroline ^a   Edwards, Julie ^b   Clarke, Carl E ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; PLACEBO;

ADVERSE EVENT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; EPISODIC MIGRAINE; HUMAN; MIGRAINE; PAIN INTENSITY; PRIORITY JOURNAL; QUALITY OF LIFE; SYSTEMATIC REVIEW; TRANSFORMED MIGRAINE;

EID: 85041718453     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011616     Document Type: Article

References (39)

1. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. First International Porto Pirgos Conference on Advances in Neuroscience 2005;26(5):785-93. [DOI: 10.1016/j.neuro.2005.01.017]
2. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group. Botulinum toxin type A prophylactic treatment of episodic migraine: A randomized, double-blind, placebo-controlled exploratory study. Headache 2007;47(4):486-99. [DOI: 10.1111/j.1526-4610.2006.00624.x]
3. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30(7):793-803. [DOI: 10.1177/0333102410364676]
4. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population - Burden, diagnosis, and satisfaction with treatment. Neurology 2008;71(8):559-66. [DOI: 10.1212/01.wnl.0000323925.29520.e7]
5. British Medical Association and the Royal Pharmaceutical Society. British National Formulary (BNF). Available from www.bnf.org.
6. Brin MF, Hallett M, Jankovic J. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins, 2002.
7. Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 2014;34(11):853-69. [DOI: 10.1177/0333102414527648]
8. Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 2008;48(6):900-13. [DOI: 10.1111/j.1526-4610.2007.00953.x]
9. Cherkin DC, Wheeler KJ, Barlow W, Deyo RA. Medication use for low back pain in primary care. Spine (Phila Pa 1976) 1998;23:607-14. [DOI: 10.1097/00007632-199803010-00015]
10. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125-33. [DOI: 10.1016/j.pain.2003.10.008]
11. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30(7):804-14. [DOI: 10.1177/0333102410364677]
12. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. Drug therapy 2002;346:257-70. [DOI: 10.1056/NEJMra010917]
13. Goodsell D. SNARE Proteins. Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB). November 2013. Available from http://www.rcsb.org/pdb/101/motm.do?momID=167. [DOI: 10.2210/rcsb_pdb/mom_2013_11]
14. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [DOI: 10.1136/bmj.39489.470347.AD]
15. Hayton MJ, Santini AJ, Hughes PJ, Frostick SP, Trail IA, Stanley JK. Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. Journal of Bone & Joint Surgery 2005;87(3):503-7. [DOI: 10.2106/JBJS.D.01896]
16. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
17. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl. 7):1-96. [DOI: 10.1111/j.1468-2982.1991.tb00021.x/10.1111/j.1468-2982.1991.tb00022.x]
18. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition, 1st revision. Cephalalgia 2004;24(Suppl 1):1-160. [DOI: 10.1111/j.1468-2982.2004.00653.x]
19. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia 2013;33(9):629-808. [DOI: 10.1177/0333102413485658]
20. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;40:277-80. [DOI: 10.1212/WNL.40.2.277]
21. Keizer SB, Rutten HP, Pilot P, Morré HH, v Os JJ, Verburg AD. Botulinum toxin injection versus surgical treatment for tennis elbow: a randomized pilot study. Clinical Orthopaedics and Related Research 2002;401:125-31.
22. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD003225.pub2]
23. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology 2012;19:703-11. [DOI: 10.1111/j.1468-1331.2011.03612.x]
24. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD010609]
25. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD010608]
26. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD010610]
27. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD010611]
28. National Institute for Health and Care Excellence. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. NICE technology appraisal guidance [TA260]. Published date: June 2012. Available from http://www.nice.org.uk/guidance/ta260.
29. National Institute for Health and Care Excellence. Headaches: Diagnosis and management of headaches in young people and adults. NICE guidelines [CG150]. Published date: September 2012. Available from http://www.nice.org.uk/guidance/cg150.
30. Paterson K, Lolignier S, Wood JN, McMahon SB, Bennett DLH. Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction. Annals of Neurology 2014;75(4):591-6. [DOI: 10.1002/ana.24122]
31. Pietrobon D. Migraine: New molecular mechanisms. Neuroscientist 2005;11(4):373-86. [DOI: 10.1177/1073858405275554]
32. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000;85:101-5. [DOI: 10.1016/S0304-3959(99)00264-X]
33. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Annals of Neurology 2008;64:274-83. [DOI: 10.1002/ana.21427]
34. Smith HS, Audette J, Royal MA. Botulinum toxin in pain management of soft tissue syndromes. Clinical Journal of Pain 2002;18:S147-54. [DOI: 10.1097/00002508-200211001-00006]
35. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. Journal of Headache and Pain 2010;11(4):289-99. [DOI: 10.1007/s10194-010-0217-0]
36. Victor T, Hu X, Campbell J, Buse D, Lipton R. Migraine prevalence by age and sex in the United States: A life-span study. Cephalalgia 2010;30(9):1065-72. [DOI: 10.1177/0333102409355601]
37. Vo AH, Satori R, Jabbari B, Green J, Killgore WDS, Labutta R, et al. Botulinum toxin type-A in the prevention of migraine: A double-blind controlled trial. Aviation Space and Environmental Medicine 2007;78(5):B113-8.
38. Wong SM, Hui AC, Tong PY, Poon DW, Yu E, Wong LK. Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 2005;143:793-7. [DOI: 10.7326/0003-4819-143-11-200512060-00007]
39. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, et al. Botulinum toxin for diabetic neuropathic pain: A randomised double-blind crossover trial. Neurology 2009;72:1473-8. [DOI: 10.1212/01.wnl.0000345968.05959.cf]